Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort.

Cancer - 1 Dec 2016

Mai Phuong L, Best Ana F, Peters June A, DeCastro Rosamma M, Khincha Payal P, Loud Jennifer T, Bremer Renée C, Rosenberg Philip S, Savage Sharon A

Abstract excerpt

BACKGROUND: Li-Fraumeni syndrome (LFS) is an autosomal dominant cancer predisposition syndrome characterized by a very high lifetime cancer risk and an early age at diagnosis of a wide cancer spectrum. Precise estimates for the risk of first and subsequent cancers are lacking. METHODS: The National Cancer Institute's Li-Fraumeni Syndrome Study includes families meeting the diagnostic criteria for LFS or...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adrenocortical Carcinoma
Share to Carcinoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Germ-Line Mutation

Share to Li-Fraumeni Syndrome

Share to Sarcoma

Share to Tumor Suppressor Protein p53

Share to United States

Source

Open in PubMed Open full text

Identifiers

PMID: 27496084
DOI: 10.1002/cncr.30248
PMCID: PMC5115949

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort.PMID 27496084Read ↗

Tumor Spectrum and Temporal Cancer Trends in adult carriers of Li-Fraumeni syndrome: Implications for Personalized Screening Strategies in<i>TP53</i>R337H carriersSemantic proximity Read ↗

Cancer incidence, patterns, and genotype-phenotype associations in individuals with pathogenic or likely pathogenic germline TP53 variants: an observational cohort study.Semantic proximity Read ↗

Update on Cancer Screening Recommendations for Individuals with Li–Fraumeni SyndromeSemantic proximity Read ↗

Li Fraumeni syndrome in the UK: clinical characteristics and outcomes of TP53 carriersSemantic proximity Read ↗

Inherited TP53 Mutations and the Li-Fraumeni Syndrome.Semantic proximity Read ↗

Personalized screening strategies for TP53 R337H carriers: a retrospective cohort study of tumor spectrum in Li-Fraumeni syndrome adult carriersSemantic proximity Read ↗

Cancer Risks Associated With TP53 Pathogenic Variants: Maximum Likelihood Analysis of Extended Pedigrees for Diagnosis of First Cancers Beyond the Li-Fraumeni Syndrome Spectrum.Semantic proximity Read ↗

Risk of multiple primary cancer diagnosis over age in families of Li-Fraumeni syndrome: a single institution perspectiveSemantic proximity Read ↗

Li–Fraumeni Syndrome: Mutation of TP53 Is a Biomarker of Hereditary Predisposition to Tumor: New Insights and Advances in the TreatmentSemantic proximity Read ↗

Medical guidelines for Li-Fraumeni syndrome 2019, version 1.1.Semantic proximity Read ↗

Guidelines for the Li–Fraumeni and heritable TP53-related cancer syndromesSemantic proximity Read ↗

Revisiting tumor patterns and penetrance in germline TP53 mutation carriers: temporal phases of Li–Fraumeni syndromeSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.